Multiple Myeloma

Isatuximab and daratumumab offer promising treatment options for previously treated multiple myeloma.

The trial is the first randomized phase 3 study evaluating the efficacy and safety of ciltacabtagene autoleucel patients with relapsed and lenalidomide-refractory multiple myeloma.

A panel of experts navigate the treatment landscape in multiple myeloma.

Kathryn Maples, PharmD, BCOP, provides insights regarding unmet needs in treatment for relapsed/refractory multiple myeloma.

A panel of experts explore burdens facing patients diagnosed with RRMM.

Ryan Haumschild, PharmD, MS, MBA, leads a panel surrounding individualized strategies for treating patients with relapse/refractory (RR) MM.

Many patients have baseline risk factors present at diagnosis because of older age and disease-related elements.

A better understanding of the pathogenesis of monoclonal gammopathy of clinical significance would help guide clinicians treating the complex condition.

Ryan Haumschild, PharmD, MS, MBA, leads a discussion surrounding relapsed/refractory multiple myeloma (MM).

Expert discusses the patient-reported outcomes from the GRIFFIN trial at the final study analysis after all patients completed 1 year of follow-up post maintenance therapy.

Researchers also noted an increasing rate of seroconversion with COVID-19 booster vaccination series.

Belantamab mafodotin-blmf is a first-in-class, anti-B-cell maturation antigen therapy indicated for adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies.

Elranatamab is a B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody.

In the inpatient acute care setting, oncology pharmacists maximize return on investments of oncology products, produce optimal outcomes, and ensure that quality of care is consistent and safe.

By 2019, lung cancer mortality rates decreased by 5.4% in males since 2015, while deaths from ovary cancer have also declined rapidly over the past 2 decades.

The indication is approved under accelerated approval based on response rate, and continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Understanding the novel mechanisms of multiple myeloma can help to develop better next-generation therapies that overcome drug resistance.

Rachel K. Anderson, PharmD, CSP, clinical program manager at Alliance Rx Walgreens Pharmacy, discusses the impact pharmacists have on the care journey for patients with multiple myeloma.

Immune function has been found to play a significant role in multiple myeloma.

Rami Elghandour, chairman and CEO of Arcellx, discussed the company’s investigative CAR-modified T-cell therapy.

Research indicates quadruplet regimens may be a viable option for this disease.

Omidubicel is a stem cell-based product that utilizes nicotinamide to inhibit differentiation and to increase the migration, bone marrow homing, and engraftment efficiency of hematopoietic progenitor cells.

Researchers identified a new immunotherapeutic target that may be effectively treated with CAR T-cell therapy in patients with pretreated multiple myeloma.

Two Houston Methodist cancer researchers were granted a quarter-million dollars each to study some of the most lethal forms cancer, including triple-negative breast cancer and multiple myeloma.

Belantamab mafodotin plus lenalidomide and dexamethasone was found tolerable with no new safety signals and enhanced response rates in patients with multiple myeloma.

Two Houston Methodist cancer researchers were granted a quarter of a million dollars each to study some of the most lethal cancers.

Eflapegrastism-xnst injection (Rolvedon, Spectrum Pharmaceuticals) is indicated to lower the incidence of infection, as demonstrated by febrile neutropenia, in adult patients with non-myeloid malignancies.

Study suggests that myeloma patient survival after BCMA-targeted T-cell therapy could be determined by microenvironment factors.

A high proportion of myeloid cells may contribute to recurrence in those with long progression-free survival by promoting cancer growth and/or suppressing antitumor immunity.

Final analysis of phase 2 GRIFFIN study from the Johnson & Johnson subsidiary shows the combination demonstrates stringent complete response rate for transplant-eligible patients.